Azeria Therapeutics has wound down voluntarily four years after being set up to advance University of Cambridge and Cancer Research UK work.

Azeria Therapeutics, a UK-based oncology spinout of University of Cambridge and research charity Cancer Research UK (CRUK), has wound down voluntarily and returned “a substantial amount of funds” to investors, according to BusinessWeekly.
The spinout formally made the decision to halt operations in December 2020, according to a regulatory filing, and had appointed Stephen Adshead of Smith & Williamson as the liquidator.
Shareholder Syncona had already revealed its decision to write off its investment the previous month…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in